Over the last decade, there have been many promising biomarkers such as Cystatin-C, NGAL, KIM-1 that assess the acute renal dysfunction.8 The availability of these new markers offers an unprecedented opportunity for improved evaluation and management of patients with AKI. This evidence concerns the gene LCN2 and acute kidney injury.